Skip to main content
. 2019 Aug 25;60(2):188–197. doi: 10.1002/jcph.1513

Figure 1.

Figure 1

Observed and model‐predicted IL‐6–induced pSTAT3 over a dosing interval after (A) the first/single dose and (B) multiple twice‐daily doses of placebo, upadacitinib, or tofacitinib. AU, arbitrary units of fluorescence; IL, interleukin; PI, prediction interval; pSTAT3, phosphorylation of signal transducer and activator of transcription proteins 3; RA, rheumatoid arthritis.